Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to ...
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · Dermavant has been developing VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older and released positive topline results from its ADORING 1 and 2 pivotal Phase 3 clinical trials in 1H 2023.
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · Dermavant’s novel product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug ...
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · OGN. VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis....
Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%. October 28, 2024 at 9:25 AM EDT. The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE ...
Organon Completes Acquisition of Dermavant, including …
JERSEY CITY, N.J., October 28, 2024 -- (BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the...
Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · JERSEY CITY, N.J.-- (BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, …
Roivant dermatology subsidiary to be acquired by Organon
Sep 18, 2024 · Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis. The medicine is also awaiting ...
Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant...
Organon pays up to $1.2B to acquire Dermavant and its steroid …
Sep 18, 2024 · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in...